Zacks Investment Research Downgrades Sino Biopharmaceut (SBMFF) to Hold

Sino Biopharmaceut (OTCMKTS:SBMFF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, January 10th.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Sino Biopharmaceut (OTCMKTS:SBMFF) opened at $1.95 on Wednesday. Sino Biopharmaceut has a fifty-two week low of $0.72 and a fifty-two week high of $1.98.

WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/sino-biopharmaceut-sbmff-downgraded-to-hold-at-zacks-investment-research/1822579.html.

Sino Biopharmaceut Company Profile

Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.

Get a free copy of the Zacks research report on Sino Biopharmaceut (SBMFF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.